- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07775235
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Assessment of Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The primary feature of idiopathic inflammatory myopathies (IIM) is inflammation of muscles, yet extra-muscular manifestations are common such as interstitial lung disease (ILD). Based on both muscular and extra-muscular features, patients can fall into different types of IIMs, including broad subtypes of dermatomyositis (DM), polymyositis (PM), inclusion-body myositis (IBM) and immune-mediating necrotizing myopathies (IMNM). Particular subtypes such as dermatomyositis patients positive for anti-melanoma differentiation-associated protein 5 (anti-MDA5) are most commonly associated with rapidly progressive lung involvement and high mortality, with survival at 1 year being less than 60% despite current available treatment. Treatment for IIM patients involves immunosuppression, though there is no consensus or treatment guidelines available for different subtypes, particularly for myositis-associated RP-ILD. Despite several trials having shown increased efficacy with more aggressive immunosuppressive regimes, mortality still remains high. There is thus an unmet need with regards to treatment of patients with IIM, particularly for myositis-associated RP-ILD.
There is an urgent need to improve outcomes in myositis-associated RP-ILD. Till date, there are no randomised controlled trials that investigate therapy of myositis-associated RP-ILD likely due to the low incidence of the disease. Current best level of evidence for therapies come from single-arm prospective cohort studies with comparison with historical controls. Recent studies using combination therapy to target different aspects of these pathological processes have demonstrated increased efficacy compared to single target alone. This shows that appropriate selection of targets with subsequent combination blockade will be beneficial in treatment of patients with myositis associated RP-ILD. Hence, the investigators propose the utilization of rituximab to block the B-cell involvement, tacrolimus to target T-cells, tofacitinib to block interferon signaling with steroids due to their effects on both the innate and adaptive system in the treatment of myositis-associated RP-ILD. Such combination therapy allows precise targeting of pathways responsible for pathophysiology of the disease, without high individual dosages and hence reducing potential side effects. Till date there are no prospective studies that look into current combination of steroids, tacrolimus, tofacitinib and rituximab in the patients with myositis-associated RP-ILD. However, a drawback for increased immunosuppression is infection, particularly with cytomegalovirus (CMV). The investigators will employ a prophylactic treatment strategy to mitigate the risk of increased infection following higher intensity immunosuppression.
The primary end point will be survival rate at 6 months from initiation of treatment.
Secondary end points include improvement of clinical status, biochemical markers, radiological appearance and parameters on lung function test. Secondary end points also include adverse events rate including side effects from treatment and infection rates.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Mohamad Fadhli Bin Masri, MD PhD
- Número de telefone: 6576 2609
- E-mail: mohamad.fadhli@mohh.com.sg
Locais de estudo
-
-
-
Singapore, Cingapura
- Recrutamento
- Singapore General Hospital
-
Contato:
- Mohamad Fadhli Bin Masri, MD PhD
- Número de telefone: 6576 2609
- E-mail: mohamad.fadhli@mohh.com.sg
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age of 21 years or above;
- Diagnosis of myositis associated rapidly progressive interstitial lung disease
Exclusion Criteria:
- Age of less than 21 year old;
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Treatment group
Patients with immune-mediated myositis-associated rapidly progressive interstitial lung disease undergoing treatment with combined immunosuppressive treatment
|
Combination treatment regimen lasting 6 months with A) Steroids: Starting with Intravenous methylprednisolone (500mg once daily for three days) followed by tapering dose of prednisolone B) Rituximab (1000mg given at the start of treatment and 1000mg 2 weeks after the first dose) C) Tacrolimus D) Tofacitinib
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All-cause mortality at 6 months from treatment initiation
Prazo: 6 months
|
Proportion of total participants who demise from all cause till 6 months from treatment initiation (percentage of all participants)
|
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in clinical status through Modified Medical Research Council Dyspnea Scale
Prazo: 6 months
|
The Modified Medical Research Council (mMRC) Dyspnea Scale will be used to rate participants' functional status at start of treatment and at 6 months post treatment (0 to 4).
|
6 months
|
|
Change in clinical status through requirement of supplemental oxygen at 6 months
Prazo: 6 months
|
Proportion of participants who require oxygen supplementation at the start of treatment and 6 months post treatment (percentage of all participants).
|
6 months
|
|
Safety of treatment regimen in participants
Prazo: 6 months
|
Number of adverse infection events experienced by participants
|
6 months
|
|
Safety of treatment regimen in participants
Prazo: 6 months
|
Number of adverse haematological events leading to change of medication as per managing physician
|
6 months
|
|
Safety of treatment regimen in participants
Prazo: 6 months
|
Number of adverse biochemical events leading to change of medication as per managing physician
|
6 months
|
|
Change in biochemical markers of disease activity
Prazo: 1 year
|
Levels of C-reactive protein (mg/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year
|
1 year
|
|
Change in biochemical markers of disease activity
Prazo: 1 year
|
Levels of Erythrocyte sedimentation rate (mm/h) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Prazo: 1 year
|
Levels of Ferritin (ug/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Prazo: 1 year
|
Levels of Lactate dehydrogenase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Prazo: 1 year
|
Levels of Creatine kinase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Prazo: 1 year
|
Levels of Aldolase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso
- Doenças Musculares
- Doenças Neuromusculares
- Doenças Respiratórias
- Doenças pulmonares
- Doenças Pulmonares Intersticiais
- Miosite
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos policíclicos
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Macrolídeos
- Lactonas
- Pregadienetriols
- Anticorpos, monoclonais, derivados de murinos
- Rituximabe
- Prednisolona
- Tacrolimo
- tofacitinibe
Outros números de identificação do estudo
- 2024/2307
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .